Loading study record…
The goal of this study is to learn how CBD affects drinking in people who drink alcohol regularly. Researchers want to see if CBD can help people drink less and reduce problems related to alcohol use.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-04-03
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Your participation will include up to five in-person visits over about 13 weeks, including a screening visit, a visit to get your medication, a midpoint visit, an experimental lab session, and a final follow-up visit. You will be assigned to a study medication which you will take daily for 8 weeks while completing daily surveys and weekly virtual check-ins with the research team. During the experimental lab session visit, you will be offered alcohol to drink at the bar lab.
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Interventions
Dose: Approximately 200mg of full-spectrum CBD (\<0.3% THC) Active Ingredients: Full spectrum hemp extract Other Ingredients: Hemp seed oil, glycerin, gelatine.
Hemp-derived, full-spectrum cannabidiol · Ecofibre USA/Ananda HempDose: Approximately 200mg of broad-spectrum CBD, (0% THC) Active Ingredients: Broad spectrum hemp extract Other Ingredients: Hemp seed oil, glycerin, gelatine.
Hemp-derived, broad-spectrum cannabidiol · Ecofibre USA/Ananda HempActive Ingredients: N/A Other Ingredients: Hemp seed oil, glycerin, gelatine.
100% Hemp Seed Oil · Ecofibre USA/Ananda HempEligibility
primary outcomes
Time frame: Week 8
Number of drinks (between 0-8) subjects choose to self-administer during the Bar Lab Alcohol Self-Administration Task at the week 8 study visit.
Time frame: Baseline, Week 4, Week 8, and Week 12
Drinks Per Drinking Day (DPDD) during the 12-week study period as reported on Timeline Follow Back at Baseline (prior to treatment), Week 4, Week 8, and Week 12.
Time frame: Baseline, Week 4, Week 8, and Week 12
Phosphatidylethanol (PEth) concentration in blood samples collected at Baseline (prior to treatment), Week 4, Week 8, and Week 12.
secondary outcomes
Time frame: Baseline, Week 8
This summary score will be calculated for change from baseline to follow-up for each of the four ANA Negative Emotionality Measures (Beck Depression Inventory-II, Beck Anxiety Inventory, State-Trait Anxiety Inventory and Drinker Inventory of Consequences-2R) . We will first subtract baseline raw scores from follow-up raw scores for each measure. The summary score will be comprised of the average of the standardized Z scores of the change scores created for each of the four measures. Z scores will range from -3 to 3 after adjusting for outliers, with higher average Z scores indicating a worse outcome.
other outcomes
Time frame: Baseline, Week 8
Gut microbial diversity from fecal samples collected at Baseline (prior to treatment) and Week 8.
Time frame: Baseline, 8 Weeks
Lipopolysaccharide Binding Protein levels in blood samples collected at Baseline (prior to treatment) and Week 8.
Time frame: Baseline, 8 Weeks
CD14 levels in blood samples collected at Baseline (prior to treatment) and Week 8.
Publications
No exact PMID-linked public article is currently readable locally.